What is Antengene?
Antengene Corporation Limited (SEHK: 6996.HK) is a global, R&D-driven biopharmaceutical company dedicated to developing innovative first-in-class/best-in-class therapeutic medicines for cancer and other critical illnesses. Operating under the vision of "Treating Patients Beyond Borders," Antengene is committed to delivering advanced anti-cancer drugs to patients across the Asia Pacific and worldwide. Since its inception in 2017, the company has achieved 23 IND approvals in the US and Asia, and submitted 6 NDAs in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in China, South Korea, Singapore, and Australia. Antengene boasts a robust pipeline of 15 clinical and pre-clinical assets, developed through strategic partnerships and in-house discovery, holding global rights on 10 programs and Asia Pacific rights on 5 programs.
How much funding has Antengene raised?
Antengene has raised a total of $238M across 3 funding rounds:
Series A
$21M
Series B
$120M
Series C
$97M
Series A (2017): $21M with participation from Huagai Capital, Tigermed, Qiming Venture Partners, and TF Capital
Series B (2019): $120M led by Boyu Capital
Series C (2020): $97M supported by Fidelity Management & Research Company, GL Ventures, Qiming Venture Partners, Boyu Capital, and GIC
Key Investors in Antengene
Boyu Capital
Boyu Capital is a leading alternative asset management firm specializing in private equity, public equities, and venture capital, with a focus on the healthcare sector. They provide catalytic capital to high-potential businesses.
Qiming Venture Partners
Qiming Venture Partners is a prominent venture capital firm that invests in the healthcare and technology sectors. They are known for supporting innovative companies with significant growth potential.
Fidelity Management & Research Company
Fidelity Investments is a global financial services provider offering a wide range of investment resources. They support companies across various sectors, contributing to their financial objectives.
What's next for Antengene?
With substantial enterprise-level backing and a recent strategic investment, Antengene is well-positioned for its next phase of growth. The company's focus on innovative oncology treatments and its expanding pipeline suggest a strategic direction towards further clinical development and market penetration. Future endeavors will likely involve leveraging its approved therapies, such as XPOVIO®, and advancing its diverse portfolio of assets. The company's commitment to global R&D and commercialization, particularly in the Asia Pacific region, indicates a strategic intent to solidify its position as a leading biopharmaceutical entity.
See full Antengene company page
